141626-35-9
Chemical Structure
Debutyldronedarone
Synonym(s): SR35021
- CAS No.: 141626-35-9
- Formula:C27H36N2O5S
- Molecular Weight:500.65
IUPAC Name: N-(2-butyl-3-(4-(3-(butylamino)propoxy)benzoyl)benzofuran-5-yl)methanesulfonamide
InChIKey: IJVZZGIAELTWBB-UHFFFAOYSA-N
SMILES: O=C(C1=CC=C(OCCCNCCCC)C=C1)C=2C=3C=C(C=CC3OC2CCCC)NS(=O)(=O)C
Biological Activity: Debutyldronedarone (SR35021) is a Cytochrome P450 enzyme inhibitor and a Thyroid Hormone Receptor inhibitor, and it is a metabolite of Dronedarone (HY-A0016). Debutyldronedarone inhibits the binding of T3 to TRα1 and TRβ1. Debutyldronedarone reduces the incidence of reperfusion-induced ventricular fibrillation in anesthetized rats, while decreasing their heart rate and blood pressure. Debutyldronedarone can be used in studies related to ventricular fibrillation and atrial fibrillation[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Debutyldronedarone | Debutyldronedarone (SR35021) is a Cytochrome P450 enzyme inhibitor and a Thyroid Hormone Receptor inhibitor, and it is a metabolite of Dronedarone (HY-A0016). Debutyldronedarone inhibits the binding of T3 to TRα1 and TRβ1. Debutyldronedarone reduces the incidence of reperfusion-induced ventricular fibrillation in anesthetized rats, while decreasing their heart rate and blood pressure. Debutyldronedarone can be used in studies related to ventricular fibrillation and atrial fibrillation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Debutyldronedarone-d7 | Debutyldronedarone-d7 (SR35021-d7) is the deuterated-labeled Debutyldronedarone (HY-12753). Debutyldronedarone (SR35021) is a Cytochrome P450 enzyme inhibitor and a Thyroid Hormone Receptor inhibitor, and it is a metabolite of Dronedarone (HY-A0016). Debutyldronedarone inhibits the binding of T3 to TRα1 and TRβ1. Debutyldronedarone reduces the incidence of reperfusion-induced ventricular fibrillation in anesthetized rats, while decreasing their heart rate and blood pressure. Debutyldronedarone can be used in studies related to ventricular fibrillation and atrial fibrillation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Debutyldronedarone-d6 hydrochloride | 99.27% | Debutyldronedarone-d6 hydrochloride (SR35021-d6 hydrochloride) is the deuterated-labeled Debutyldronedarone (HY-12753). Debutyldronedarone (SR35021) is a Cytochrome P450 enzyme inhibitor and a Thyroid Hormone Receptor inhibitor, and it is a metabolite of Dronedarone (HY-A0016). Debutyldronedarone inhibits the binding of T3 to TRα1 and TRβ1. Debutyldronedarone reduces the incidence of reperfusion-induced ventricular fibrillation in anesthetized rats, while decreasing their heart rate and blood pressure. Debutyldronedarone can be used in studies related to ventricular fibrillation and atrial fibrillation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Therapeutic Goods Administration. Australian Public Assessment Report for Dronedarone Hydrochloride, submission PM-2008-3045-3, Australian Government Department of Health and Ageing, 2008.
- [2]. Van Beeren HC, et al. Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. Endocrinology. 2003 Feb;144(2):552-8. [Content Brief]
